Celldex Therapeutics, Inc. (NASDAQ:CLDX) Rating Reiterated by Aegis

Aegis reiterated their buy rating on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in a report issued on Thursday, June 29th.

A number of other brokerages have also recently issued reports on CLDX. Zacks Investment Research cut shares of Celldex Therapeutics from a buy rating to a hold rating in a research note on Tuesday, June 27th. Jefferies Group LLC reduced their price objective on shares of Celldex Therapeutics from $5.00 to $4.00 and set a hold rating for the company in a research note on Wednesday, March 15th. ValuEngine cut shares of Celldex Therapeutics from a sell rating to a strong sell rating in a research note on Saturday, June 3rd. Cowen and Company restated a buy rating on shares of Celldex Therapeutics in a research report on Tuesday, June 6th. Finally, HC Wainwright restated a buy rating and set a $6.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, March 15th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. Celldex Therapeutics presently has an average rating of Hold and an average price target of $6.75.

Shares of Celldex Therapeutics (NASDAQ:CLDX) remained flat at $2.30 on Thursday. 923,689 shares of the company’s stock were exchanged. The firm’s 50-day moving average price is $2.44 and its 200 day moving average price is $3.08. Celldex Therapeutics has a 52-week low of $2.20 and a 52-week high of $5.02. The firm’s market capitalization is $287.74 million.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.28) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.28). The business had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $0.57 million. Celldex Therapeutics had a negative net margin of 1,825.82% and a negative return on equity of 53.10%. Analysts forecast that Celldex Therapeutics will post ($1.11) EPS for the current year.

WARNING: “Celldex Therapeutics, Inc. (NASDAQ:CLDX) Rating Reiterated by Aegis” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/07/29/aegis-reaffirms-buy-rating-for-celldex-therapeutics-inc-nasdaqcldx-updated-updated-updated.html.

Several large investors have recently added to or reduced their stakes in CLDX. Meditor Group Ltd increased its position in Celldex Therapeutics by 39.9% in the second quarter. Meditor Group Ltd now owns 5,800,000 shares of the biopharmaceutical company’s stock valued at $14,326,000 after buying an additional 1,654,100 shares in the last quarter. Creative Planning increased its position in Celldex Therapeutics by 12.2% in the second quarter. Creative Planning now owns 80,136 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 8,716 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Celldex Therapeutics by 0.9% in the first quarter. Goldman Sachs Group Inc. now owns 280,425 shares of the biopharmaceutical company’s stock valued at $1,012,000 after buying an additional 2,453 shares in the last quarter. Credit Suisse AG increased its position in Celldex Therapeutics by 139.8% in the first quarter. Credit Suisse AG now owns 243,073 shares of the biopharmaceutical company’s stock valued at $877,000 after buying an additional 141,689 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its position in Celldex Therapeutics by 10.5% in the first quarter. Metropolitan Life Insurance Co. NY now owns 70,650 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 6,695 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply